Outlook Therapeutics (NASDAQ:OTLK) Given Neutral Rating at Chardan Capital

Chardan Capital reissued their neutral rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a report published on Monday morning, MarketBeat reports.

A number of other brokerages also recently issued reports on OTLK. Ascendiant Capital Markets reduced their price target on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Outlook Therapeutics in a report on Friday, November 29th. Finally, BTIG Research lowered their price target on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Outlook Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $42.34.

Outlook Therapeutics Stock Down 8.0 %

Shares of OTLK stock opened at $1.66 on Monday. The firm has a market cap of $39.27 million, a price-to-earnings ratio of -0.16 and a beta of 0.46. Outlook Therapeutics has a 52-week low of $0.87 and a 52-week high of $12.85. The company’s 50 day moving average is $5.06 and its 200 day moving average is $6.59.

Insider Buying and Selling at Outlook Therapeutics

In related news, CFO Lawrence A. Kenyon purchased 5,000 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were acquired at an average price of $5.69 per share, for a total transaction of $28,450.00. Following the purchase, the chief financial officer now owns 5,946 shares of the company’s stock, valued at $33,832.74. This trade represents a 528.54 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Outlook Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC purchased a new position in Outlook Therapeutics in the 2nd quarter worth $75,000. Christensen King & Associates Investment Services Inc. acquired a new position in shares of Outlook Therapeutics in the third quarter valued at about $55,000. Barclays PLC increased its holdings in shares of Outlook Therapeutics by 677.4% in the third quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after purchasing an additional 18,249 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Outlook Therapeutics in the second quarter worth about $232,000. Finally, XTX Topco Ltd acquired a new stake in shares of Outlook Therapeutics during the third quarter worth about $199,000. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.